Clinical Trials Directory

Trials / Conditions / Relapsed Small Cell Lung Cancer

Relapsed Small Cell Lung Cancer

9 registered clinical trials studyying Relapsed Small Cell Lung Cancer — 3 currently recruiting.

StatusTrialSponsorPhase
RecruitingBiomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
NCT06681220
VA Office of Research and DevelopmentPhase 1 / Phase 2
RecruitingLurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
NCT06496048
Luye Pharma Group Ltd.Phase 3
RecruitingStudy of LY01610 in Patients With Recurrent Small Cell Lung Cancer
NCT06128837
Luye Pharma Group Ltd.Phase 3
Active Not RecruitingClinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotec
NCT05153239
PharmaMarPhase 3
WithdrawnVenetoclax and Irinotecan in Relapsed/Refractory SCLC
NCT04543916
Virginia Commonwealth UniversityPhase 1 / Phase 2
CompletedSafety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients
NCT04421352
CStone PharmaceuticalsPhase 1
TerminatedImmune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
NCT04610658
H. Lee Moffitt Cancer Center and Research InstitutePhase 1
UnknownA Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Seco
NCT04757779
First People's Hospital of HangzhouPhase 2
TerminatedCombination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (
NCT03406715
H. Lee Moffitt Cancer Center and Research InstitutePhase 2